Clinical Trial

A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The research hypothesis is that the tumor-free survival rate of intermediate-risk breast cancer patients exempted from RNI is not inferior to that of those receiving RNI. Patients with intermediate-risk breast cancer have a relatively low local-regional recurrence rate whether they undergo RNI or not.Patients were randomly assigned to the RNI group and the non-RNI group.After radiotherapy,the patients are followed the efficacy and toxicities of radiotherapy are evaluated.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-27.
Trial Details
NCT Number NCT07385365
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Breast Cancer
Enrollment 3,142 participants
Start Date 2026-02-01
Primary Completion 2032-12-31 (estimated)
Study Completion 2042-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-11